Recombinant Human EGFR protein (hFc Tag)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human EGFR protein (hFc Tag) (Eg0495)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

hFc Tag

Activity

not tested

Cat no : Eg0495

---

Validation Data Gallery

• 

  Purity of Recombinant Human EGFR was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human EGFR protein Leu25-Ser645 (Accession# P00533-1) with a human IgG1 Fc tag at the C-terminus.
• GeneID: 1956
• Accession: P00533-1
• PredictedSize: 94.6 kDa
• SDS-PAGE: 100-130 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTKs) and exerts critical functions in epithelial cell physiology. EGFR is a receptor of tyrosine kinase (RTK). It is consisted of a C-terminus intracellular region that possesses the kinase activity, and an N-terminus extracellular ligand-binding site, a hydrophobic transmembrane domain. EGFR is frequently mutated and/or overexpressed in different types of human cancers and is the target of multiple cancer therapies currently adopted in the clinical practice. Mutations in this gene are associated with lung cancer.

References:

1. Schlessinger J. et al. (2014). Cold Spring Harb Perspect Biol. 6(3).
2. Yoshida T. et al. (2010). Biochem Pharmacol. 80(5):613-23.
3. Wilson KJ. et al. (2012). Growth Factors. 30(2):107-16.
4. Sigismund S. et al. (2018). Mol Oncol. 12(1):3-20.